Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months…
Articles by Marisa Wexler, MS
Treatment with Endeavor Biomedicines’ experimental oral therapy taladegib (ENV-101) improved lung function in people with idiopathic pulmonary fibrosis…
The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as…
Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of…
Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary…
The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat…
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis…
LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation…
The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis…
September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring…